Evidence map›Paper›PMID 33605081›Full record

SynthesisJournal of the International AIDS Society2021

Missed opportunities for sexually transmitted infections testing for HIV pre-exposure prophylaxis users: a systematic review.

Jason J Ong, Hongyun Fu, Rachel C Baggaley, Teodora E Wi, Joseph D Tucker, M Kumi Smith, Sabrina Rafael, Jane Falconer, Fern Terris-Prestholt, Ioannis Mameletzis and 1 more

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06446752 (A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06446752 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women

TypeinterventionalSponsorUniversity of WashingtonRan2024 to 2027Enrolled1,100ConditionsGonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus, Gonorrhea of CervixArmsBexsero, Placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Prevalence ofEpidemiology and infection · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Jason J OngLondon School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-5784-7403
Hongyun FuEastern Virginia Medical School, Norfolk, VA, USA.
Rachel C BaggaleyWorld Health Organization, Geneva, Switzerland.
Teodora E WiWorld Health Organization, Geneva, Switzerland.ORCID 0000-0002-7640-9166
Joseph D TuckerLondon School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-2804-1181
M Kumi SmithUniversity of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5861-8100
Sabrina RafaelLondon School of Hygiene and Tropical Medicine, London, UK.
Jane FalconerLondon School of Hygiene and Tropical Medicine, London, UK.
Fern Terris-PrestholtLondon School of Hygiene and Tropical Medicine, London, UK.
Ioannis MameletzisWorld Health Organization, Geneva, Switzerland.
Phillipe MayaudLondon School of Hygiene and Tropical Medicine, London, UK.
London School of Hygiene & Tropical Medicine · GBWorld Health Organization · CHEastern Virginia Medical School · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionGiven the synergistic relationship between HIV and sexually transmitted infections (STI), the integration of services has the potential to reduce the incidence of both HIV and STIs. We explored the extent to which STI testing has been offered within HIV pre-exposure prophylaxis (PrEP) programmes worldwide.

methodsWe conducted a systematic review of PrEP programmes implementing STI testing services in nine databases. We approached PrEP implementers for additional unpublished data and implementation details. Descriptive statistics were used to present the characteristics of STI testing within PrEP programmes. Content analysis of the input from PrEP implementers was conducted to summarize the barriers to and facilitators of STI testing.

resultsOf 9,161 citations, 91 studies conducted in 32 countries were included: 69% from high-income countries (HICs) and 64% from programmes targeting men who have sex with men (MSM) and transgender women (TGW) only. The majority of programmes (70%, 64/91) conducted STI testing before the initiation of PrEP. The most common STIs tested were gonorrhoea (86%, 78/91), chlamydia (84%, 76/91) and syphilis (84%, 76/91). The majority provided STI testing at three-month intervals (70%, 53/76, for syphilis; 70% 53/78, for chlamydia; 68%, 53/78, for gonorrhoea). Relative to low- and middle-income countries (LMICs), a higher proportion of PrEP programmes in HICs offered testing for gonorrhoea (92% vs. 71%, p < 0.05), chlamydia (92% vs. 64%, p < 0.01), syphilis (87% vs. 75%, p < 0.05), hepatitis A (18% vs. 4%, p < 0.05) and hepatitis C (43% vs. 21%, p < 0.05); offered testing for a higher number of STIs (mean 3.75 vs. 3.04, p < 0.05); and offered triple (throat, genital/urine and anorectal) anatomical site screening (54% vs. 18%, p < 0.001). Common implementation challenges included costs, access to STI diagnostics, programme logistics of integrating STI testing into PrEP delivery models and lack of capacity building for staff involved in PrEP provision.

conclusionsSignificant gaps and challenges remain in the provision of STI testing services within HIV PrEP programmes. We recommend more active integration of STI testing and management into PrEP programmes, supported by standardized practice guidelines, staff capacity building training and adequate funding. This could lead to improved sexual health and HIV outcomes in key populations.

Indexed as

Pre-Exposure ProphylaxisAdultCohort StudiesDelivery of Health CareFemaleHIV InfectionsHumansMaleSexual HealthSexually Transmitted DiseasesHIVpre-exposure prophylaxissexual healthsexually transmitted infectionsSTI testingsystematic review

Identifiers

PMID33605081
PMCPMC7893146
OpenAlexW3131886905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.